



Determination of the Role of HA, HYAL and HA- Receptor Expression in A Rat Model of Middle Cerebral Artery Occlusion

Ahmed Al Q^{1,2*}, John J G², Jerzy K³ and Mark S²

¹Al-Ahliyya Amman University, Amman, Jordan

²The School of Biology, Chemistry and Health Science, Manchester Metropolitan University, Manchester, UK

³Department of Neurology, Stroke Unit, Institute D'Investigacio Biomedico De Belvitge, Barcelona, Spain

***Correspondence author:** Dr. Ahmed Al Qteishat, Al- Ahliyya Amman University, Amman, Jordan, Tel: + 962 791874625; Email: a.qteishat@ammanu.edu.jo

Received Date: April 10, 2019; **Published Date:** April 18, 2019

Abstract

Hyaluronan (HA), a component of the extracellular matrix, has been implicated in regulating angiogenesis and cell proliferation, migration, and signaling. We used the rat MCAO to show hyaluronan accumulation in stroke-affected areas. Using RT-PCR and Western blotting we showed up-regulation of hyaluronidase-1 and 2 between 1h and 21 days after stroke. Hyaluronidase-1 was up regulated earlier than hyaluronidase-2. RHAMM and CD44 receptors were also increased after stroke. Immunohistochemistry results, showed an association of hyaluronidases 1/2 and hyaladherins with neurons in the infarcted and peri-infarcted regions and hyaluronidase-1 with micro vessels. HA synthesis and degradation in the stroke hemisphere might have an impact on neuronal survival, angiogenesis and general tissue remodeling after stroke.

Keywords: MCAO; rat stroke model; hyaladherins; hyaluronidase 1 and 2; RHAMM; CD44

Abbreviations: EC: Endothelial Cells; RHAMM: Receptor for Hyaluronan-Mediated Motility; HA: Hyaluronan; RT-PCR: Reverse Transcription-Polymerase Chain Reaction; MCAO: Middle Cerebral Artery Occlusion.

Introduction

Stroke is the third leading cause of death and is a major source of chronic disability [1-3]. Recent evidence suggests that angiogenesis in the penumbra region is correlated with patient survival and protection from the later consequences of stroke such as dementia [4-6].

Angiogenesis involves growth of new endothelial cells (EC) and is initiated by angiogenic molecules produced by stroke and penumbra tissue. One of these molecules, hyaluronan (HA) has differing roles in angiogenesis depending on its size. High molecular weight HA (n-HA) can promote wound healing in damaged tissue whereas oligosaccharides of specific size (3-10 disaccharides; o-HA) stimulate EC proliferation and migration [7-9], and operates by stimulation of a receptor-mediated process [10,11]. CD44 binds both n-hyaluronan and o-hyaluronan, leading to the organization and turnover of the extracellular matrix at the cell surface. The receptor for

hyaluronan-mediated motility (RHAMM) is found in intracellular compartments and in the cell membrane and on binding hyaluronan initiates cellular signaling resulting in motility [12,13].

Hyaluronan turnover may increase in stroke tissue as a result of tissue remodeling and, therefore, we have investigated the expression of hyaluronan, hyaluronan metabolizing enzymes and hyaladherins in a rat middle cerebral artery occlusion (MCAO) model of stroke.

Material and methods

Animals and anesthesia

Stroke was induced in non-pregnant female Sprague-Dawley rats weighing 230-270g that suffer less during ischemia/traumatic insult owing to higher endogenous steroid levels reducing free radical damage [14]. The animals were housed at 211C with ad libitum access to food and water. Animal welfare was conducted according to regulations of the Real Decreto 223:1988 in accordance with the National Institutes of Health, Public Health Service Policy of the Care and Handling of Laboratory Animals and the experimental protocol approved by the Ethical Committee of the Hospital Universitari de Bellvitge, Barcelona.

Middle cerebral artery occlusion

Cerebral ischemia was induced by distal, permanent occlusion of the middle cerebral artery by electro cautery [15]. Sets of six animals (three each for morphological and biochemical studies) were killed at 1, 4, 12 and 24 h, and 3, 4, 7 and 21 days, and at 1 and 2 months for immunohistochemistry. These times were chosen to reflect the major pathophysiological events, inflammation, angiogenesis and wound recovery occurring after stroke. Animals were guillotined and brain samples snap frozen in liquid nitrogen and stored at 701C. Infarcted and peri-infarcted tissue from the grey and white matter, and control areas in the contralateral hemisphere, were removed. The peri-infarcted area was identified as in our previous report [16].

Reverse transcription-polymerase chain reaction (RT-PCR)

Total cellular RNA was extracted and first strand cDNA generated from animals at the above time points using a standard kit (Promega, Southampton, UK). Sequences for polymerase chain reaction primers for hyaluronidase-1, forward (F) 5'-CCT CTG GGG CTT CTA CCT CT and reverse (R) 5'-CCA CAG GAC TTG CTC TAG-3'; hyaluronidase- 2, F

5'-CCT CTG GGG CTT CTA CCT CT-3' and R 5'-CTG AAC ACG GAA GCT CAC AA-3'; CD44, F 5'-GTG GGC CAA CAA AGA ACA CT-3' and R 5'-TGG GAG CAG GCC CAA ATT A-3'; receptor for hyaluronan-mediated motility, F 5'-GAA AGG GAA GAA GGG TGA AC-3' and R 5'-TGC CAA AAT CTG ATG CTG AA-3'; S16, F 5'-GAT GCA AGA AGA CAG CCA CA-3' and R 5'-GGA CAG CCG GAT AGC ATA AA-3'. cDNA samples were amplified (35 cycles) under standard conditions [17]. All polymerase chain reaction experiments were repeated at least twice and representative results shown. The S16 housekeeping gene was used as a control to show equality of amplification.

Extraction of protein from tissue samples and Western blotting

The method is described in detail elsewhere [11]. After separation, proteins were stained with donated antibodies to hyaluronidase-1 (mouse monoclonal [18]), hyaluronidase-2 (rabbit polyclonal [19]), receptor for hyaluronan-mediated motility (rabbit polyclonal [20]) (the accompanying reference describes the characterization of the antibody and the donor) and CD44 (mouse monoclonal, Santa Cruz Biotechnologies, Santa Cruz, California, USA). Antibodies were used at a dilution of 1:1000 except anti-CD44 (1:500). Alphaactin control (Calbiochem, San Diego, California, USA) was run with each set of samples.

After staining with peroxidase-conjugated secondary antibody (anti-rabbit or anti- mouse, 1:1000) for 1 h at room temperature, blots were developed using the ECL detection system (Amersham, Aylesbury, UK). The intensity of staining relative to a- actin was measured by densitometry. Results are semi-quantitative and given as a numerical change compared with the control (1/41.0). Experiments were performed at least twice and a representative example is shown. The specificity of antibodies was confirmed using human positive control Jurkat cell lysate and bands of the expected mass (hyaluronidase-1 57 kDa, hyaluronidase-2 60 kDa, receptor for hyaluronan-mediated motility 55 kDa and CD44 80 kDa) were seen.

Affinity: histochemical localization of hyaluronan

Sections were incubated overnight with hyaluronan-specific biotinylated probe (a gift of the Seikagaku Corporation, Chuo-ku, Tokyo, Japan) as described elsewhere [9]. Specificity of staining was tested by digesting control sections with Streptomyces hyaluronidase in the presence of protease inhibitors.

Immunohistochemical localization of proteins

The avidin-biotin-peroxidase method was used for immunohistochemical localization of hyaluronidase 1/2, receptor for hyaluronan-mediated motility and CD44 as described elsewhere [17]. Specificity of the immunoreaction was tested by replacement with pre-immune serum.

Results

Expression of hyaluronidase

Diffuse staining of hyaluronan was seen in the extracellular matrix. Increased staining was seen in infarcted and peri-infarcted tissues especially at the boundary zone of the stroke (Figure 1a and b). Increased hyaluronan was visible 48 h after stroke and persisted for 21 days. Control sections pre-digested with hyaluronidase were negatively stained (data not shown).




Figure 1: Hyaluronan and associated proteins: distribution in the brain after stroke; hyaluronan expression at the boundary zone (arrows) between infarcted and peri-infarcted grey matter 4 h (a) and 24 h (b) after stroke. (c) (i) Weak staining for hyaluronidase-1 in neurons in normal looking grey matter; (ii) strong nuclear staining in a neuron from infarcted tissue (arrow) and a blood vessel (broken arrow) after 1h. (d) (i) Weak neuronal staining for hyaluronidase-2 in normal looking grey matter; (ii) strong intracellular staining in neurons from infarcted tissue (arrows) after 7 days. (e) (i) Weak neuronal staining for receptor for hyaluronan-mediated motility in normal looking grey matter; (ii) strong intracellular staining in neurons from peri-infarcted tissue (arrows) after 24 h. (f) (i) Weak neuronal staining for CD44 in neurons in normal looking grey matter; (ii) strong staining in neurons from infarcted tissue (arrows) after 7 days.

Expression of hyaluronidase-1

Hyaluronidase-1 mRNA was up-regulated 1 h after stroke and remained increased after 21 days (range of increase 15-fold to 18-fold) in infarcted and peri-infarcted areas. Hyaluronidase-1 protein expression was increased between 24 h and 7 days in both grey and white matter.

Expression was greater in infarcted tissue at earlier time points and in peri-infarcted tissue at later time points (range 2- to 4-fold).

Little staining was noted for hyaluronidase-1 in normal tissue but increased nuclear staining at early time points

after stroke in micro-vessels in infarcted and peri-infarcted tissue (Figure 1c). Staining persisted up to 21 days after stroke.

Expression of hyaluronidase-2

Hyaluronidase-2 mRNA was up-regulated 24 h after stroke in peri-infarcted and infarcted tissue and reached a maximum (15-fold) at 3 days. It remained elevated in stroke tissue at 21 days but returned to control levels in the peri-infarcted area. Hyaluronidase-2 protein expression was increased between 24 h and 7 days in grey and white matter, and was greatest in peri-infarcted areas (range 1.5 to 5-fold). Increased intracellular staining of neurons distributed throughout the peri-infarcted area was seen up to 4 days after stroke (Figure 1d).

Expression of receptor for hyaluronan-mediated motility

MRNA was up-regulated in peri-infarcted and infarcted tissue 1 h after stroke and was still elevated after 21 days (approximately 20-fold). Receptor for hyaluronan-mediated motility protein expression was increased between 12 h and 7 days after stroke in both peri-infarcted and infarcted grey matter and between 1 h to 7 days in white matter (range 1- to 8-fold). Weak cytoplasmic staining for receptor for hyaluronan-mediated motility in neurons in the corpus callosum was seen in control sections. Increased intracellular staining was seen in infarcted and peri-infarcted neurons (Figure 1e).

Expression of CD44

CD44 mRNA was up-regulated 1 h after stroke and remained increased 21 days later in both peri-infarcted and infarcted tissue (range 20-fold). CD44 protein was up-regulated between 1 h and 7 days in both grey and white matter after stroke. Expression was greater in peri-infarcted tissue (range 2- to 6-fold). In control tissue there was weak staining for CD44 in neurons in grey matter. In peri-infarcted tissue there was staining for CD44 in blood vessels and some microglia after 12 h and in neurons after 24 h in the V and VI cortical layers (Figure 1f). After 48 h, staining was observed in dying neurons and all staining disappeared after 96 h. We also observed increased expression of hyaluronan synthase-1 (between 24 h and 21 days) and hyaluronan synthase-2 (between 3 and 21 days) and staining in inflammatory cells and in glia in peri-infarcted regions (data not shown).

Discussion

Increased staining for hyaluronic throughout the infarcted area in the rat brain was seen, indicating up-regulated

synthesis after stroke. In the rat embryo, hyaluronic directs migration and proliferation in the cerebral cortex, suggesting a role in the establishment of neuronal pathways. Hyaluronic was increased in the cerebrospinal fluid of patients with head injury and cerebral infarction together with accumulation in the superficial layer of the cerebral cortex [21]. Our results suggest increased synthesis of hyaluronic in infarcted tissue, perhaps due to the reestablishment of the extracellular matrix during tissue remodeling after ischaemic stroke. This study used female rats that undergo a cyclic variation in estrogen levels known to affect glycosaminoglycan synthesis in the endometrium [22] but as we compared stroke and contralateral tissues from the same rats, this should not have had a bearing on our findings. No studies show such a hormonal effect in the brain.

Hyaluronidases are involved in tissue remodeling during embryonic development, tumor invasion and wound healing. Hyaluronidase-1 mRNA was up-regulated after 1 h and remained increased up to 21 days in stroke-affected tissue. Hyaluronidase-2 was up-regulated 24 h after stroke and reached maximum levels after 3 days. Hyaluronidases 1/2 protein expression was elevated in the grey and white matter of all stroke-affected tissue. This suggests that breakdown of high molecular weight hyaluronic is a feature of stroke pathophysiology. Immunohistochemistry demonstrated increased Hyaluronidases expression in neurons in infarcted tissue. The results suggest a rapid degradation of hyaluronic at the site of tissue injury after stroke, which could enhance neuronal plasticity of nerve cell bodies or possibly stimulate angiogenesis in peri-infarcted regions. Hyaluronidase-2 generates a 20 kDa fragment internalized by receptor-mediated endocytosis and delivered to lysosomes where further degradation by hyaluronidase-1 occurs [7]. Although hyaluronidase-2 is also present in many tissues, it is not normally found in the brain owing to gene inactivation by hyper methylation [23]. Hyaluronidases- 2 may have undergone gene re-activation after stroke. As hyaluronic levels did not appear to decrease over the time of the study there must have been resynthesizes through the action of hyaluronic synthase 1/2 (detected after 24 h and 3 days, respectively, unpublished data) thus generating high molecular weight hyaluronic (RMM 3.9_106).

Cell signaling through receptor for hyaluronan-mediated motility and CD44 mediates neuronal migration, astrocyte motility and angiogenesis [11,24]. Binding of o-hyaluronic to receptor for hyaluronan-mediated motility and CD44 in human endothelial cell lines in vitro activated mitogen activated protein kinase (ERK1/2) and initiated mitogenesis [11]. Receptor for hyaluronan-mediated

motility mRNA was up-regulated after 1 h in both peri-infarcted and infarcted tissue and remained increased 21 days after stroke compared with normal contralateral hemisphere. Increased expression was seen in infarcted tissue, associated with neuronal cytoplasm. Receptor for hyaluronan-mediated motility expression might enhance calmodulin-mediated signalling to cytoskeletal elements in neurons [25]. CD44 is involved in multiple responses to inflammation including leukocyte recruitment, cell-matrix interactions and matrix remodeling. CD44 mRNA was increased after 12 h in stroke-affected areas and remained increased up to 21 days after stroke. CD44 protein associated with neurons and micro-vessels in the stroke hemisphere. The concurrent induction of CD44 and hyaluronan in the ischaemic area may potentiate the inflammatory effect of hypoxia. CD44 expression is regulated by hyaluronan fragments, interleukin-1b and tumor necrosis factor- α , which are increased after stroke [6]. Previous studies have shown that CD44-deficient mice were protected against cerebral ischaemia injury, in association with reduced expression of interleukin-1b. Increased CD44 expression in micro-vessels together with hyaluronidase-1 up-regulation could activate angiogenesis.

Conclusion

The results presented here show hyaluronan accumulation, increased expression of the enzymes responsible for hyaluronan degradation and up-regulation of hyaluronan receptors after induced stroke in the rat. This may reflect tissue remodelling after stroke and may have an important role in modulating angiogenesis and neuronal survival.

References

1. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM (1994) Role of angiogenesis in patients with ischemic cerebral stroke. *Stroke* 25(9): 1794-1798.
2. Krupinski J, Kumar P, Kumar S, Kaluza J (1996) Increased expression of TGF- β 1 in brain tissue after ischemic stroke in humans. *Stroke* 27(5): 852-857.
3. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, et al. (1997) A putative role for platelet derived growth factor in angiogenesis and neuroprotection after ischaemic stroke in humans. *Stroke* 28(3): 564-573.
4. Krupinski J, Stroemer P, Slevin M, Marti E, Kumar P, et al. (2003) Three-dimensional structure and survival of newly formed blood vessels after focal cerebral ischemia. *Neuroreport* 14(8): 1171-1176.
5. Sbarbati A, Pietra C, Baldassari AM, Guerrini U, Ziviani L, et al. (1996) The microvascular system in ischemic cortical lesions. *Acta Neuropathol* 92(1): 56-63.
6. Slevin M, Krupinski J, Kumar P, Gaffney J, Kumar S (2005) Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection. *J Cell Mol Med* 9(1): 85-102.
7. Stern R (2003) Devising a pathway for hyaluronan catabolism: are we there yet? *Glycobiology*; 13(12): 105R-115R.
8. West DC, Hampson IN, Arnold F, Kumar S (1985) Angiogenesis induced by degradation products of hyaluronic acid. *Science* 228(4205): 1324-1326.
9. West DC, Lees VC, Fan TP (1995) Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. *Lab Invest* 73(2): 259-266.
10. Slevin M, Krupinski J, Kumar S, Gaffney J (1998) Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. *Lab Invest*; 78(8): 987-1003.
11. Slevin M, Kumar S, Gaffney J (2002) Angiogenic oligosaccharides of hyaluronan induces multiple signal pathways affecting vascular endothelial cell mitogenic and wound healing responses. *J Biol Chem*; 277(43): 41046-41059.
12. Day AJ, Prestwich GD (2002) Hyaluronan-binding proteins; tying up the giant. *J Biol Chem* 277(7): 4585-4588.
13. Hall CL, Turley EA (1995) Hyaluronan; RHAMM mediated cell locomotion and signaling in tumorigenesis. *J Neurooncol*; 26(3): 221-229.
14. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, et al. (1998) Gender-linked brain injury in experimental stroke. *Stroke* 29(1): 159-165.
15. Tamura Y, Saito S, Hataro M, Lucchesi BR (1989) Limitation of myocardial infarct size by polyethylene glycol-conjugated superoxide dismutase in a canine model of 90min coronary occlusion followed by 4 days of reperfusion. *Kokyu To Junkan* 37(2):201-208.

16. Mitsios N, Gaffney J, Heywood S, Matthias R, Kumar P, et al. (2006) Apoptosis after ischemic stroke. *Cell Biochem Biophys*.
17. Al'Qteishat A, Gaffney J, Krupinski J, Rubio F, West D, et al. (2006) Changes in hyaluronan production and metabolism following ischaemic stroke in man. *Brain* 129(Pt 8): 2158-76.
18. Shuttleworth TL, Wilson MD, Wicklow BA, Wilkins JA, Triggs-Raine BL (2002) Characterization of the murine hyaluronidase gene region reveals complex organization and cotranscription of Hyal1 with downstream genes, Fus2 and Hyal3. *J Biol Chem* 277(25): 23008-23018.
19. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E (2004) CD44 interaction with Na⁺ -H⁺ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. *J Biol Chem* 2004; 279(26): 26991-27007.
20. Lynn BD, Li X, Cattini PA, Turley EA, Nagy JI (2001) Identification of sequence, protein isoforms, and distribution of the hyaluronan-binding protein RHAMM in adult and developing rat brain. *J Comp Neurol* 439(3): 315-330.
21. Laurent T, Fraser JR (1992) Hyaluronan. *FASEB J* 6(7): 2397-2404.
22. Telbach M, Lois A, Salamonsen, Van Damme MP (2002) The influence of ovarian steroids on ovine endometrial glycosaminoglycans. *Glycoconjugate J* 19(6): 385-394.
23. Lepperdinger G, Mullegger J, Kreil G(2001) Hyal2--less active but more versatile?. *Matrix Biol* 2001; 20(8): 509-514.
24. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, et al (2001) Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA- mediated motility in endothelial cell function and angiogenesis. *J Biol Chem* 2001; 276(39): 36770-36778.
25. Hascall V, Majors AK, De La Motte CA, Evanko SB, Wang A, et al. (2004) Intracellular hyaluronan: a new frontier for inflammation. *Biochim Biophys Acta* 1673(1-2): 3-12.